“BTG continues to advance its leadership in Interventional Medicine by actively listening to our customers and providing creative solutions to meet their clinical needs,” said Peter Pattison, Interventional Oncology General Manager, BTG. “Several years ago, we began scientific collaboration with Philips to evaluate the benefits of better image-guided therapy and this venture resulted in the ability to calibrate Philips’ imaging software to LC Bead LUMI™. The clinical impact of the BTG / Philips collaboration is now helping interventional radiologists and multi-disciplinary teams make enhanced treatment decisions for patients with liver cancer.”

Ronald Tabaksblat, Business Leader, Imaging Guided Therapy Systems, Philips commented “Minimally-invasive therapy procedures provide key benefits for healthcare systems and patients, and intelligent image guidance is an essential part of these procedures. We aim to continuously improve Image Guided Therapy and our collaboration with BTG to provide enhanced visibility and guidance during interventional embolization procedures is another important milestone in this exciting journey to help deliver excellent treatment and enhanced patient care.”


LC Bead LUMI™ was cleared for clinical use in the US in December 2015 after extensive laboratory testing based on the clinical foundation of its predicate device, LC Bead ®.

BTG and Philips will showcase their advancements in interventional oncology at the upcoming symposium on Clinical Interventional Oncology (CIO), taking place Feb. 6 – 7 in Hollywood, FL. For information on BTG, visit www.btg-im.com, and to learn more about Philips integrated solutions for diagnostics and therapeutic oncology, please visit www.philips.com/io

Back to HCB News

More HCB News